SGHT Stock Price, Sight Sciences, Inc. Quote, Chart

Market Summary

USD5.62-0.02

Market Closed

-0.35%

SGHT Stock Price

View Fullscreen

SGHT RSI Chart

SGHT Valuation

Market Cap

279.5M

Price/Earnings (Trailing)

-5.03

Price/Sales (Trailing)

3.45

EV/EBITDA

-3.5

Price/Free Cashflow

-5.83

SGHT Price/Sales (Trailing)

SGHT Profitability

EBT Margin

-68.39%

Return on Equity

-46.21%

Return on Assets

-33.33%

Free Cashflow Yield

-17.17%

SGHT Fundamentals

SGHT Revenue

Revenue (TTM)

81.1M

Rev. Growth (Yr)

-8.72%

Rev. Growth (Qtr)

-6.28%

SGHT Earnings

Earnings (TTM)

-55.5M

Earnings Growth (Yr)

36.77%

Earnings Growth (Qtr)

17.98%

Breaking Down SGHT Revenue

Last 7 days

7.8%

Last 30 days

9.7%

Last 90 days

19.5%

Trailing 12 Months

-41.5%

How does SGHT drawdown profile look like?

SGHT Financial Health

Current Ratio

13.29

Debt/Equity

0.26

Debt/Cashflow

-1.49

SGHT Investor Care

Shares Dilution (1Y)

1.24%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	75.3M	81.5M	82.8M	81.1M
2022	55.2M	59.9M	65.5M	71.3M
2021	33.0M	38.3M	43.6M	49.0M
2020	0	0	0	27.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sight Sciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	hayden jeremy b.	sold	-24,851	5.079	-4,893	chief legal officer
Apr 03, 2024	bauerlein alison	sold	-51,414	5.079	-10,123	chief financial officer
Apr 03, 2024	park sam boong	sold	-17,339	5.079	-3,414	chief operating officer
Apr 03, 2024	badawi paul	sold	-63,848	5.079	-12,571	president and ceo
Apr 03, 2024	badawi david	sold	-15,887	5.079	-3,128	chief technology officer
Feb 14, 2024	hayden jeremy b.	sold	-	-	-151,869	chief legal officer
Feb 14, 2024	bauerlein alison	sold	-	-	-315,421	chief financial officer
Feb 14, 2024	park sam boong	sold	-	-	-151,869	chief operating officer
Feb 14, 2024	badawi paul	sold	-	-	-390,187	president and ceo
Feb 14, 2024	badawi david	sold	-	-	-108,645	chief technology officer

Which funds bought or sold SGHT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.53	-12,000	4,000	-%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	240	10,560	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 15, 2024	Concurrent Investment Advisors, LLC	new	-	218,021	218,021	0.01%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.59	2,857,790	7,609,360	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	19,084	55,429	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-69,000	-	-%
Feb 15, 2024	Legal & General Group Plc	reduced	-63.55	-23,446	29,749	-%
Feb 15, 2024	Palo Alto Investors LP	new	-	896,756	896,756	0.08%

Are Funds Buying or Selling SGHT?

Are funds buying SGHT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SGHT

No. of Funds

Unveiling Sight Sciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	kck ltd.	9.5%	4,646,866	SC 13G/A
Feb 13, 2024	bank of america corp /de/	6.5%	3,174,134	SC 13G
Feb 07, 2024	ubs group ag	5.9%	2,879,863	SC 13G
Jan 10, 2024	d1 capital partners l.p.	0%	0	SC 13G/A
Dec 01, 2023	encrantz staffan	8.3%	4,022,118	SC 13D/A
Feb 14, 2023	hep partners llc	0.0%	0	SC 13G/A
Feb 14, 2023	badawi paul	11.8%	5,691,953	SC 13G/A
Feb 13, 2023	kck ltd.	9.9%	4,776,232	SC 13G
May 19, 2022	encrantz staffan	8.5%	4,022,118	SC 13D/A
Apr 18, 2022	shd gp ii, llc	0.55%	262,695	SC 13D/A

Recent SEC filings of Sight Sciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Sight Sciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

Sight Sciences, Inc. News

Latest updates

Sight Sciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-6.3%	18,751,500	20,009,000	23,471,000	18,824,000	20,543,500	18,677,000	17,229,000	14,881,000	14,685,000	13,101,000	12,535,000	8,635,000	8,643,000	8,651,000	3,502,000
Gross Profit	-7.8%	15,976,000	17,332,000	20,090,000	15,776,000	16,879,000	15,749,000	14,493,000	11,848,000	12,743,000	11,039,000	10,230,000	6,334,000	-	6,031,000	1,417,000
Operating Expenses	-11.9%	27,085,000	30,743,000	35,277,000	33,344,000	33,931,500	37,594,000	37,357,000	34,041,000	27,459,000	25,069,000	21,306,000	17,990,000	-	13,386,000	9,107,000
S&GA Expenses	-10.7%	23,658,000	26,504,000	30,056,000	28,675,000	28,698,000	31,541,000	31,431,000	28,395,000	23,090,000	20,790,000	17,760,000	14,550,000	-	11,228,000	7,664,000
R&D Expenses	-19.2%	3,427,000	4,239,000	5,221,000	4,669,000	5,233,500	6,053,000	5,926,000	5,646,000	4,369,000	4,279,000	3,546,000	3,440,000	-	2,158,000	1,443,000
EBITDA Margin	9.5%	-0.61	-0.67	-0.80	-0.99	-1.14	-1.22	-1.25	-1.25	-1.18	-0.73	-0.83	-0.96	-1.15	-	-
Interest Expenses	-5.7%	1,351,000	1,432,000	1,349,000	1,276,000	1,223,500	1,131,000	1,065,000	1,046,000	1,078,000	1,122,000	1,082,000	1,084,000	-	538,000	549,000
Income Taxes	-87.2%	10,000	78,000	8,000	14,000	10,000	19,000	9,000	9,000	98,000	16,000	22,000	52,000	-	8,000	6,000
Earnings Before Taxes	17.6%	-10,681,000	-12,957,000	-14,746,000	-17,053,000	-16,897,000	-22,210,000	-23,834,000	-23,254,000	-15,838,000	-17,153,000	-17,593,000	-12,188,000	-	-8,089,000	-8,310,000
EBT Margin	8.1%	-0.68	-0.74	-0.87	-1.06	-1.21	-1.30	-1.34	-1.34	-1.28	-0.79	-0.90	-1.05	-1.25	-	-
Net Income	18.0%	-10,691,000	-13,035,000	-14,754,000	-17,067,000	-16,907,000	-22,229,000	-23,843,000	-23,263,000	-15,936,000	-17,169,000	-17,615,000	-12,240,000	-9,105,000	-8,097,000	-8,316,000
Net Income Margin	8.1%	-0.69	-0.75	-0.87	-1.06	-1.21	-1.30	-1.34	-1.34	-1.29	-1.29	-1.23	-1.15	-1.26	-	-
Free Cashflow	33.4%	-6,748,000	-10,132,000	-13,586,000	-17,509,000	-15,631,000	-20,464,000	-18,647,000	-22,193,000	-10,879,000	-16,799,000	-12,701,000	-12,974,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-5.7%	167	177	185	197	213	225	241	259	280	291	53.00	73.00
Current Assets	-6.2%	163	174	182	194	210	222	238	255	277	288	47.00	71.00
Cash Equivalents	-4.4%	138	145	155	167	185	200	220	239	261	271	36.00	62.00
Inventory	-15.1%	8.00	9.00	8.00	7.00	6.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00
Net PPE	5.4%	2.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
Liabilities	-6.3%	46.00	50.00	49.00	50.00	53.00	52.00	49.00	47.00	48.00	45.00	52.00	44.00
Current Liabilities	-14.5%	12.00	14.00	14.00	15.00	18.00	17.00	14.00	12.00	14.00	10.00	12.00	9.00
Long Term Debt	-6.1%	32.00	34.00	34.00	33.00	33.00	33.00	33.00	33.00	33.00	32.00	32.00	32.00
LT Debt, Current	-	2.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-6.1%	32.00	34.00	34.00	33.00	33.00	33.00	33.00	33.00	33.00	32.00	32.00	32.00
Shareholder's Equity	-5.4%	120	127	136	146	160	173	192	212	232	246	-	-
Retained Earnings	-3.8%	-294	-284	-271	-256	-239	-222	-200	-176	-153	-137	-119	-90.04
Additional Paid-In Capital	0.9%	415	411	407	403	399	395	392	388	385	383	3.00	1.00
Shares Outstanding	1.7%	49.00	48.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	40.00	10.00	10.00
Float	-	-	-	302	-	-	-	290	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	34.0%	-6,484	-9,828	-13,489	-17,383	-15,502	-20,192	-18,305	-21,966	-10,722	-16,512	-12,436	-12,870	-	-	-
Share Based Compensation	-10.3%	3,460	3,856	3,742	3,523	3,234	3,223	3,532	2,974	1,976	1,899	931	277	-	-	-
Cashflow From Investing	13.2%	-264	-304	-97.00	-126	-129	-272	-342	-227	-157	-287	-265	-104	-	-	-
Cashflow From Financing	218.6%	376	118	766	-156	812	186	158	92.00	91.00	252,702	-54.00	-210	-	-	-

SGHT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 81,056	$ 71,331
Cost of goods sold	11,881	12,361
Gross profit	69,175	58,970
Operating expenses:
Research and development	17,556	22,859
Selling, general and administrative	108,893	120,065
Total operating expenses	126,449	142,924
Loss from operations	(57,274)	(83,954)
Interest expense	(5,408)	(4,466)
Other income (expense), net	7,245	2,225
Loss before income taxes	(55,437)	(86,195)
Provision for income taxes	110	47
Net loss and comprehensive loss	$ (55,547)	$ (86,242)
Net loss per share attributable to common stockholders-basic	$ (1.14)	$ (1.8)
Net loss per share attributable to common stockholders-diluted	$ (1.14)	$ (1.8)
Weighted-average shares of common stock outstanding-basic	48,628,940	47,849,058
Weighted-average shares of common stock outstanding-diluted	48,628,940	47,849,058

SGHT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 138,129	$ 185,000
Accounts receivable, net of allowance for credit losses of $1,024 and $1,186 at December 31, 2023 and 2022, respectively	14,289	15,148
Inventory, net	7,849	6,114
Prepaid expenses and other current assets	2,604	3,415
Total current assets	162,871	209,677
Property and equipment, net	1,640	1,571
Operating lease right-of-use assets	1,458	1,614
Other noncurrent assets	682	211
Total assets	166,651	213,073
Current liabilities:
Accounts payable	1,731	2,688
Accrued compensation	4,528	7,352
Accrued and other current liabilities	3,774	7,777
Current portion - long-term debt, net	2,219	0
Total current liabilities	12,252	17,817
Long-term debt, net of current portion	31,708	33,313
Other noncurrent liabilities	2,476	1,867
Total liabilities	46,436	52,997
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock par value of $0.001 per share; 10,000,000 authorized; no shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock par value of $0.001 per share; 200,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 49,131,363 and 48,298,138 shares issued and outstanding as of December 31, 2023 and 2022, respectively	49	48
Additional paid-in-capital	414,956	399,271
Accumulated deficit	(294,790)	(239,243)
Total stockholders' equity	120,215	160,076
Total liabilities and stockholders' equity	$ 166,651	$ 213,073

About Sight Sciences, Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

CEO	Mr. Paul Badawi
WEBSITE	sightsciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	250

Sight Sciences, Inc. Frequently Asked Questions

What is the ticker symbol for Sight Sciences, Inc.? What does SGHT stand for in stocks?

SGHT is the stock ticker symbol of Sight Sciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sight Sciences, Inc. (SGHT)?

As of Tue Apr 23 2024, market cap of Sight Sciences, Inc. is 279.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGHT stock?

You can check SGHT's fair value in chart for subscribers.

What is the fair value of SGHT stock?

You can check SGHT's fair value in chart for subscribers. The fair value of Sight Sciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sight Sciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGHT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sight Sciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SGHT is over valued or under valued. Whether Sight Sciences, Inc. is cheap or expensive depends on the assumptions which impact Sight Sciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGHT.

What is Sight Sciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, SGHT's PE ratio (Price to Earnings) is -5.03 and Price to Sales (PS) ratio is 3.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGHT PE ratio will change depending on the future growth rate expectations of investors.